My Forever Portfolio: 4 Spectacular Stocks You Can Buy Now and Never Sell
Summary
Parkev emphasizes a shift in investment strategy when moving from a short-term to a long-term horizon. In Parkev's view, while valuation remains an essential component of the decision-making process, its relative importance decreases over a long-term period as the compounding effect of competitive advantages takes over. Parkev uses discounted cash flow models to identify stocks that are currently trading below their intrinsic value while possessing nearly insurmountable barriers to entry.
Parkev highlights four specific stocks that fit this 'buy and hold forever' criteria: Eli Lilly, Visa, Coca-Cola, and Colgate-Palmolive. For each, Parkev identifies a clear 'moat'—whether it be pharmaceutical R&D, massive payment networks, global distribution infrastructure, or brand loyalty. Parkev provides specific price targets based on fair value calculations, suggesting that all four are currently undervalued. Parkev concludes by advising that even 'forever' stocks require occasional monitoring to ensure their structural competitive advantages remain intact.
Mentioned Stocks
Reasoning: Parkev points to Coca-Cola's century-long brand loyalty and its vast distribution and marketing network as key strengths. Parkev highlights its exclusive relationships with major entities like Disney and McDonald's, and recent gains like KFC. Parkev estimates the fair value at $100 per share, compared to a current market price of $96.
Reasoning: Parkev describes Visa's two-sided network of 4 billion cards and millions of merchants as a massive competitive advantage that is extremely difficult for innovators to replicate. Parkev notes that merchants are essentially forced to accept Visa due to its scale. Parkev calculates a fair value of $471 per share, while the current market price is approximately $423.
Reasoning: Parkev views Eli Lilly as a robust pharmaceutical giant with a decades-long track record of R&D success, emphasizing that it is not a 'one-hit wonder' despite the current hype around weight-loss drugs. Parkev calculates a fair value of $1,662 per share, which is well above the current market price of $1,366. Parkev mentions owning the stock and being interested in buying more.
Reasoning: Parkev notes that Colgate-Palmolive benefits from high barriers to entry due to its capital-intensive manufacturing and established shelf space in a slow-growth industry. Parkev finds the valuation attractive, trading at $97 while estimating a fair value of over $120 per share.